Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43

Benzinga · 3d ago
Stifel analyst Paul Matteis initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $43.